title: Bronchial arterial infusion is an effective therapeutic modality for centrally located early-stage lung cancer: results of a pilot study.
abstract: OBJECTIVE
  This pilot study was done to assess the effectiveness of bronchial arterial infusion (BAI) as a therapeutic modality for centrally located early-stage lung cancer.
  
  
  METHODS
  Seven patients who had endoscopically evaluated, centrally located early-stage squamous cell lung carcinoma, including three patients with synchronous multiple primary lung cancers, were offered BAI with cis-diamminedichloroplatinum (CDDP; dosage, 50 to 150 mg/body, 35 to 100 mg/m2), a radical therapeutic method, as an alternative to a resection.
  
  
  RESULTS
  All early-stage lesions showed complete remission within 1 to 6 weeks (median, 3.3 weeks) after BAI. In the three patients with multiple lung cancers, BAI was used to treat accessible early-stage lesions, although a surgical resection was required for advanced lesions. Three of the seven patients suffered from severe bronchial ulcers after BAI. Six of the patients in the study had no disease relapse to date at a median follow-up time of 19.8 months (range, 11 to 32 months), but the other patient died of a pulmonary hemorrhage 3 months after BAI.
  
  
  CONCLUSIONS
  Based on our findings, BAI with CDDP should be reappraised as an effective therapeutic modality for centrally located early-stage lung cancer and as an acceptable primary treatment.
authors.affiliation: Department of Surgery II, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Osaki
authors.forename: T
authors.initials: T
authors.lastname: Hanagiri
authors.forename: R
authors.initials: R
authors.lastname: Nakanishi
authors.forename: I
authors.initials: I
authors.lastname: Yoshino
authors.forename: S
authors.initials: S
authors.lastname: Taga
authors.forename: K
authors.initials: K
authors.lastname: Yasumoto
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001981:Bronchial Arteries; D001999:Bronchoscopy; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial / Q000009:adverse effects; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy; D010865:Pilot Projects; D014057:Tomography, X-Ray Computed
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin